Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tyra Biosciences, Inc. on May 31, 2024, covering events that occurred on May 29, 2024. The filing details the outcomes of the Company's 2024 Annual Meeting of Stockholders held on that date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance matters rather than financial performance.
Material Changes
The primary material change reported is the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation. This amendment eliminates the personal liability of the Company's officers for monetary damages for any breach of fiduciary duty, to the extent permitted by Delaware General Corporation Law. The amendment became effective upon filing with the Delaware Secretary of State on May 29, 2024.
Outlook, Risks, and Voting Results
Management commentary and forward-looking guidance are not included in this filing. The following matters were submitted to a vote of security holders:
- Election of Directors: Three Class III directors were elected for a three-year term: Melissa McCracken, Ph.D., Jake Simson, Ph.D., and Rehan Verjee. All received significant "For" votes (ranging from approximately 41.7 million to 42.2 million) with minimal votes withheld.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received 49,046,425 votes "For" and only 859 votes "Against."
- Amendment to Certificate of Incorporation: The proposal to exculpate certain officers was approved with 41,217,753 votes "For" and 1,059,388 votes "Against."
Key Facts for Investor Verification
- Verify the effective date of the officer liability exemption amendment (May 29, 2024) and its specific limitations under Delaware law.
- Confirm the composition of the Board of Directors following the election of the three new Class III directors.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for detailed legal language regarding officer liability.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.